Oncomine NGS Solutions for Hemato-oncology Research

Unlocking more blood cancer insights with NGS

Each year, an estimated 1.28 million people are diagnosed with a blood cancer, accounting for roughly 6% of all new cancer cases worldwide1.

 

These challenging disorders are genetically complex, often harboring a range of somatic mutations. In recent years, studies have uncovered a multitude of disease-associated genetic alterations that are fueling precision-oncology research and progressing hope for a better future in managing these diseases.


Benefit of NGS for hemato-oncology research

Traditional molecular testing involves iterative single-analyte approaches, complex workflows, all of which results in variable, often lengthy, turnaround times.

 

Next-generation sequencing (NGS) has revolutionized the study of  hematologic malignancies by streamlining genetic profiling. NGS allows for efficient, simultaneous assessment of multiple genetic biomarkers with a single assay. Advancements in NGS automation enable results in as few as 1-2 days.


Hemato-oncology research NGS solutions

Deepen your understanding of hematological malignancies with an unmatched offering of NGS testing solutions and capabilities. We offer a range of NGS assays for applications across a spectrum of disease research areas. Each assay is provided as part of a complete solution on our trusted NGS platforms, the Ion GeneStudio S5 System and the Ion Torrent Genexus System.


Integrated analysis software streamlines reporting and facilitates the interpretation of results. Unmatched workflow automation simplifies the testing process, enabling any laboratory to adopt NGS testing—including those without prior experience and expertise.

Oncomine Myeloid Assays GX v2

Oncomine Myeloid MRD Assays (RUO)

Oncomine Immune Repertoire Assays


Customer presentations

Moving toward a brighter future in hemato-oncology 

Our customers and collaborators are making incredible research advancements, disrupting traditional paradigms, and bringing forth new insights and approaches for understanding hematologic malignancies. Our NGS technology has been embraced by some of the top minds in the world to address the most pressing challenges is these disease research areas.

Implementing NGS for the Study of Lymphoid Malignancies

Gerard Frigola, MD

Hematopathologist
Hospital Clinic, IDIBAPS,
University of Barcelona

AMP 2023 Workshop On-Demand: NGS for Myeloid Malignancy Analysis

Cecilia Yeung, MD

Professor, Translational Science and Therapeutics Division
Medical Director, Fred Hutch Clinical Testing Labs
Fred Hutchinson Cancer Center

Utility of NGS in Lymphoid Malignancies

Dr. Michael Krigstein

Consultant Haematologist
MBBS(Hons) FRACP FRCPA MCncrSc
SydPath, St Vincent’s Hospital

The Time is Now for NGS-Based Clonality Testing

Dr. Michael Hummel

Charite

NGS for B Cell Receptor Sequencing in Multiple Myeloma

Dr. Arthur Kowalik

Holy Cross Cancer Center

Lymphoma Molecular Characterization - Assessing the Journey to Answers

Dr. Marianne Grantham

Barts Health NHS Trust

Advances in Immune Repertoire Sequencing for the Study of Lymphoid Neoplasm

Dr. John DeCoteau

Professor of Pathology & Laboratory Medicine, Medical Director, Advanced Diagnostic Research Laboratory, University of Saskatchewan

How NGS Can Rapidly Deliver Key Insights for Myeloid Neoplasms

Dr. Bevan Tandon

Director of Hematopathology
and Molecular Pathology,
Pathline Labs

Molecular Analysis in the Diagnosis and Prognosis of Hematological Malignancies

Dr. Geetha Menon

Clinical Director
HODS, Cheshire & Merseyside Cancer Network, Liverpool Clinical Laboratories.


Ready to speak to a Thermo Fisher representative?

We will be happy to answer your questions and provide a demo of our NGS solutions.

For Research Use Only. Not for use in diagnostic procedures.